Skip to main content
letter
. 2022 Sep 8;52(12):1446–1449. doi: 10.1093/jjco/hyac137

Figure 1.

Figure 1

Kaplan–Meier analysis of progression-free survival among Japanese patients enrolled in the IKEMA study. CI, confidence interval; HR, hazard ratio; Isa, isatuximab; Kd, carfilzomib-dexamethasone.